Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ginsenoside H is a preparation derived from Panax ginseng, formulated as "Ginsenoside H dripping pills." It is under clinical investigation primarily as an adjuvant therapy for advanced non-small cell lung cancer. The main active anticancer ingredient in this formulation is ginsenoside Rh2, a dammarane-type saponin (ginsenoside) known for its potential antitumor effects. Ginseng-derived ginsenosides are pharmacologically active compounds with diverse biological activities including immunomodulation, anti-cancer properties, neuroprotection, and metabolic regulation. Mechanistically, certain ginsenosides (including Rh2) modulate ion channels (such as voltage-dependent Ca²⁺/K⁺/Na⁺ channels), inhibit ligand-gated ion channels (e.g., NMDA receptors), and influence apoptosis-related pathways in cancer cells and neurons. The oral route of administration has been studied in clinical trials for the GH formulation[2][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ginsenoside h.